1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Guiyang Xintian Pharmaceutical Co. Ltd. Class A

Guiyang Xintian Pharmaceutical Co. Ltd. Class A

SSZSE:002873
7.77
CNY
+0.02
(+0.26%)
0.00EPS
1.79BMarket Cap
Oct 29Next Earn
Guiyang Xintian Pharmaceutical Co. Ltd. Class A
SZSE:002873
(Shenzhen Stock Exchange)

Recent

price

7.77

P/E

ratio

- -

div

yld

2.15%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.92
2.34
2.63
3.02
3.68
3.32
3.02
3.42
3.33
4.27
4.69
4.12
3.89
3.18
2.89
Revenue per Share
0.15
0.09
0.19
0.24
0.33
0.32
0.31
0.32
0.32
0.44
0.48
0.35
0.24
0.04
- -
Basic EPS, GAAP
-0.19
-0.13
-0.01
0.04
0.28
-0.21
0.03
-0.54
0.48
0.08
-0.23
-0.1
0.12
0.14
- -
Free Cash Flow per Basic Share
0.04
0.23
0.09
0.11
0.11
0.1
0.1
0.07
0.12
0.13
0.15
0.18
0.16
0.18
0.17
Dividend per Share
1.04
0.91
1.11
1.31
1.62
2.71
2.87
3.08
3.6
3.87
4.84
4.81
4.89
5.15
5.24
Book Value per Share
0.53
0.37
0.56
0.78
1.09
2.32
2.48
2.57
3.03
3.27
4.19
4.1
4.1
4.3
4.37
Tangible Book Value per Share
172
173
172
173
172
206
230
226
225
227
232
232
220
235
238
Basic Weighted Avg Shares
330
406
454
522
633
682
694
773
751
970
1,088
954
858
750
688
Sales/Revenue/Turnover
10.52
6.77
10.66
11.4
11.91
10.43
10.38
11.69
12.31
14.11
12.74
10.88
7.82
4.02
3.31
Operating Margin (%)
1
6
6
8
12
12
14
16
19
23
25
23
37
39
- -
Depreciation Expense
26
15
33
42
57
66
71
71
73
99
112
81
52
9
-1
Net Income, GAAP
13.09
8.54
10.7
11.92
10.99
11.39
13.48
14.66
13.38
14.52
8.1
12.49
13.88
6.74
120.27
Effective Tax Rate (%)
8
3.72
7.29
8.05
9.01
9.7
10.22
9.24
9.66
10.26
10.25
8.48
6.1
1.22
-0.09
Profit Margin (%)
68
49
58
43
50
299
329
257
298
143
109
81
135
271
123
Working Capital
6
29
65
54
10
4
4
16
160
161
162
205
228
426
275
LT Debt
178
157
191
226
279
622
661
709
827
888
1,122
1,113
1,195
1,256
1,279
Total Equity
- -
4.06
8.53
9.09
12.14
10.63
7.82
7.7
6.31
7.32
7.62
4.93
3.13
0.51
-0.04
Return on Invested Capital (%)
- -
8.03
11.68
12.18
14.83
11.02
9.04
8.46
6.57
8.39
8.29
5.49
3.89
1.4
-0.24
Return on Capital (%)
- -
8.99
19.04
20.16
22.58
14.67
11.08
10.46
9.46
11.6
11.1
7.24
4.53
0.74
-0.05
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
243
316
317
LT Borrowings
421
312
271
LT Finance Leases
5
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
244
244
244
Market Capitalization
2,422
2,470
1,787

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
651
614
565
Cash, Cash Equivalents & STI
174
167
184
Accounts Receivable, Net
268
255
205
Inventories
172
160
151
Total Current Liabilities
380
457
442
Payables & Accruals
- -
- -
- -
ST Debt
243
316
317
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.18%
9.09%
5.15%
Free Cash Flow
-247.36%
-143.17%
20.48%
Net Income, GAAP
-3.49%
-19.23%
-82.59%
Sales/Revenue/Turnover
4.56%
1.27%
-12.57%
Total Cash Common Dividend
10.49%
10.66%
18.15%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
177
264
219
197
858
2025
193
165
- -
191
750
2026
179
153
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.06
0.14
-0.04
0.24
2025
0.02
0.01
- -
-0.03
0.04
2026
0.01
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.09
0.03
0.02
0.16
2025
0.06
0.08
- -
0.02
0.18
2026
0.02
0.05
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Guiyang Xintian Pharmaceutical Co., Ltd. (002873.SZ) engages in the research, development, production, and sale of proprietary Chinese medicines primarily targeting gynecological and urological diseases, with additional coverage of oral cavity, breast and thyroid, anti-cold, heat-clearing, blood supplementation, cardiovascular, and anti-tumor conditions. The company manufactures products in various dosage forms including hard capsules, compounds, granules, gels, tablets, syrups, wines, and lotions across eight GMP-certified production lines, plus two Chinese medicine decoction piece lines; key brands encompass Kuntai capsules, Bitter Ginseng gel, Menstrual Conditioning capsules, Ningbitai capsules, Hot Shower tablets, Xia Kui Cao oral liquid, Huangbai capsules, Cold Cough capsules, Angelica oral liquid, Longzhoukou liquid, Xinlikang capsules, and Xinlikang granules. Founded in 1995 and headquartered in Guiyang, China, it listed on the Shenzhen Stock Exchange SME board in May 2017 and operates principally within the domestic Chinese market. Recent developments include receiving China clinical trial approval for a traditional chemotherapy supplemental drug, announcing 2025 semi-annual results forecasts, and electing Dong Dalun as chairman; the controlling shareholder plans to reduce up to 3.0% stake between November 2025 and February 2026, while the company agreed to acquire an additional minority stake in Shanghai Huilun Life Sciences & Technology Co., Ltd.